Product logins

Find logins to all Clarivate products below.


Biosimilars | Market Events and Forecast | Ophthalmology | 2025

In 2023, sales of branded biologics in ophthalmology exceeded $9.2 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033 forecast period, the reference brands Lucentis (ranibizumab) and Eylea (aflibercept) are set to lose patent protection, and biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for these key reference brands and their biosimilars by molecule and country / region.

Related Market Assessment Reports

Report
Dry and Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast (G7)
AMD is a leading cause of vision loss across the major markets, with wet AMD accounting for most drug-treated cases. The wet AMD market is dominated by IVT anti-VEGF or anti-VEGF / Ang-2 therapies…
Report
Biosimilars – Forecast – Oncology
In 2024, sales of branded mAb biologics in oncology exceeded $47.5 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled $5.9 billion…
Report
Biosimilars – Forecast – Forecast Methodology and General Market Assumptions
In 2024, sales of branded biologics for oncology (except G-CSFs), immunology, endocrinology, ophthalmology, neurology, osteoporosis, and respiratory indications totaled approximately $160 billion…
Report
Biosimilars – Forecast – Neurology
In 2024, sales of branded MAb biologics in neurology exceeded $12 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2024-2034 forecast period, the…
Report
Biosimilars – Forecast – Ophthalmology
In 2024, sales of branded biologics in ophthalmology exceeded $6.7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2024-2034 forecast period…